Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Long-Term Deferred Tax (2017)

RedHill Biopharma has reported Long-Term Deferred Tax over the past 1 years, most recently at $76.0 million for Q4 2017.

  • Quarterly Long-Term Deferred Tax changed N/A to $76.0 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $76.0 million through Dec 2017, changed N/A year-over-year, with the annual reading at $76.0 million for FY2017, N/A changed from the prior year.
  • Long-Term Deferred Tax was $76.0 million for Q4 2017 at RedHill Biopharma.
  • Over five years, Long-Term Deferred Tax peaked at $76.0 million in Q4 2017 and troughed at $76.0 million in Q4 2017.